OLDSMAR, Fla.--(BUSINESS WIRE)--In anticipation of its official European launch at the 14th Aesthetic & Anti-Aging Medicine World Congress (AMWC) this month, UVLrx Therapeutics™ is pleased to share its intravenous light therapy treatment system, the model UVL1500, to assist in aesthetic post-surgical and non-surgical patient recovery by reducing inflammation, pain, and accelerating wound repair. The company has started to collect patient data that showcases the benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue following invasive and non-invasive aesthetic procedures today.

“According to the International Society of Aesthetic Plastic Surgery, more than 20 million cosmetic surgical and non-surgical procedures were performed in 2014,” said Michael Harter, CEO and president of UVLrx. “The success of those procedures depends heavily on quality of recovery and patient response, which is why inflammation abatement is so important for the industry. By immediately reducing inflammation caused by an aesthetic procedure, our technology may minimize pain and accelerate healing, which in turn may lead to better results and a more satisfied post-op patient.”

Dr. Daniel Knight, MD, and Denise Moss, RN, in conjunction with White Clover Wellness & Research Center in Shreveport, Louisiana, have clinical trial results that demonstrate recovery improvement using an investigational device version of the UVLrx technology (Model UVL1000) by reducing pain, edema and erythema in several of their post-surgical/non-surgical aesthetics patients. In fact, all fifteen patients they treated recently in the clinical trial reported improvement in overall quality of life and confidence in their recovery progression. The patients’ positive perception of their improved recovery even appeared to translate into the patients’ perception of how successful the results of their aesthetic procedures were overall, in some cases even accelerating results.
In this clinical trial, patients were treated and subsequently monitored across four evaluation points: baseline and days 3, 7 and 14 post-procedure. Subjects reported improvement by day 3 evaluation, and no adverse effects have been observed. UVLrx patients reported a significant reduction in pain and presented with impressive clinical results days after undergoing non-surgical procedures such as transdermal ultrasound skin tightening, which has often been described as painful and requiring several months to observe clinical results. The level of post-procedural progress observed in this study by day 7 resembled results typically observed in months 2 and 3 post procedure.

Products and Clearances Homepage